1363 / 1498
The R
2
regimen
(Fowler at al. Lancet Oncol 2014)
Chanan-Khan, A. A. et al. J Clin Oncol; 26:1544-1552 2008
►
Preclinical data suggests that lenalidomide may augment immune effector
function and enhance rituximab mediated ADCC
►
Previously untreated advanced stage ‘indolent lymphoma’
►
n=110 (103 pts. evaluable) 57% GELF criteria for high tumour burden